367 related articles for article (PubMed ID: 29311155)
1. Increased Risk of Severe Hypoglycemic Events Before and After Cardiovascular Outcomes in TECOS Suggests an At-Risk Type 2 Diabetes Frail Patient Phenotype.
Standl E; Stevens SR; Armstrong PW; Buse JB; Chan JCN; Green JB; Lachin JM; Scheen A; Travert F; Van de Werf F; Peterson ED; Holman RR;
Diabetes Care; 2018 Mar; 41(3):596-603. PubMed ID: 29311155
[TBL] [Abstract][Full Text] [Related]
2. Confirming the Bidirectional Nature of the Association Between Severe Hypoglycemic and Cardiovascular Events in Type 2 Diabetes: Insights From EXSCEL.
Standl E; Stevens SR; Lokhnygina Y; Bethel MA; Buse JB; Gustavson SM; Maggioni AP; Mentz RJ; Hernandez AF; Holman RR;
Diabetes Care; 2020 Mar; 43(3):643-652. PubMed ID: 31882409
[TBL] [Abstract][Full Text] [Related]
3. Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Clinical Trial.
McGuire DK; Van de Werf F; Armstrong PW; Standl E; Koglin J; Green JB; Bethel MA; Cornel JH; Lopes RD; Halvorsen S; Ambrosio G; Buse JB; Josse RG; Lachin JM; Pencina MJ; Garg J; Lokhnygina Y; Holman RR; Peterson ED;
JAMA Cardiol; 2016 May; 1(2):126-35. PubMed ID: 27437883
[TBL] [Abstract][Full Text] [Related]
4. Sitagliptin does not reduce the risk of cardiovascular death or hospitalization for heart failure following myocardial infarction in patients with diabetes: observations from TECOS.
Nauck MA; McGuire DK; Pieper KS; Lokhnygina Y; Strandberg TE; Riefflin A; Delibasi T; Peterson ED; White HD; Scott R; Holman RR
Cardiovasc Diabetol; 2019 Sep; 18(1):116. PubMed ID: 31481069
[TBL] [Abstract][Full Text] [Related]
5. Associations between β-blocker therapy and cardiovascular outcomes in patients with diabetes and established cardiovascular disease.
Shavadia JS; Zheng Y; Green JB; Armstrong PW; Westerhout CM; McGuire DK; Cornel JH; Holman RR; Peterson ED
Am Heart J; 2019 Dec; 218():92-99. PubMed ID: 31715435
[TBL] [Abstract][Full Text] [Related]
6. Regional, age and sex differences in baseline characteristics of patients enrolled in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).
Bethel MA; Green JB; Milton J; Tajar A; Engel SS; Califf RM; Holman RR;
Diabetes Obes Metab; 2015 Apr; 17(4):395-402. PubMed ID: 25600421
[TBL] [Abstract][Full Text] [Related]
7. Sex differences in management and outcomes of patients with type 2 diabetes and cardiovascular disease: A report from TECOS.
Alfredsson J; Green JB; Stevens SR; Reed SD; Armstrong PW; Angelyn Bethel M; Engel SS; McGuire DK; Van de Werf F; Hramiak I; White HD; Peterson ED; Holman RR;
Diabetes Obes Metab; 2018 Oct; 20(10):2379-2388. PubMed ID: 29923323
[TBL] [Abstract][Full Text] [Related]
8. Association of obesity with cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease: Insights from TECOS.
Pagidipati NJ; Zheng Y; Green JB; McGuire DK; Mentz RJ; Shah S; Aschner P; Delibasi T; Rodbard HW; Westerhout CM; Holman RR; Peterson ED;
Am Heart J; 2020 Jan; 219():47-57. PubMed ID: 31707324
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular safety for once-weekly dulaglutide in type 2 diabetes: a pre-specified meta-analysis of prospectively adjudicated cardiovascular events.
Ferdinand KC; Botros FT; Atisso CM; Sager PT
Cardiovasc Diabetol; 2016 Feb; 15():38. PubMed ID: 26912057
[TBL] [Abstract][Full Text] [Related]
10. Hypoglycemia and Cardiovascular Outcomes in the CARMELINA and CAROLINA Trials of Linagliptin: A Secondary Analysis of Randomized Clinical Trials.
Marx N; Kolkailah AA; Rosenstock J; Johansen OE; Cooper ME; Alexander JH; Toto RD; Wanner C; Espeland MA; Mattheus M; Schnaidt S; Perkovic V; Gollop ND; McGuire DK
JAMA Cardiol; 2024 Feb; 9(2):134-143. PubMed ID: 38170502
[TBL] [Abstract][Full Text] [Related]
11. Causes of Death in a Contemporary Cohort of Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease: Insights From the TECOS Trial.
Sharma A; Green JB; Dunning A; Lokhnygina Y; Al-Khatib SM; Lopes RD; Buse JB; Lachin JM; Van de Werf F; Armstrong PW; Kaufman KD; Standl E; Chan JCN; Distiller LA; Scott R; Peterson ED; Holman RR;
Diabetes Care; 2017 Dec; 40(12):1763-1770. PubMed ID: 28986504
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular Mortality in Patients With Type 2 Diabetes and Recent Acute Coronary Syndromes From the EXAMINE Trial.
White WB; Kupfer S; Zannad F; Mehta CR; Wilson CA; Lei L; Bakris GL; Nissen SE; Cushman WC; Heller SR; Bergenstal RM; Fleck PR; Cannon CP;
Diabetes Care; 2016 Jul; 39(7):1267-73. PubMed ID: 27289121
[TBL] [Abstract][Full Text] [Related]
13. Effect of Sitagliptin on Kidney Function and Respective Cardiovascular Outcomes in Type 2 Diabetes: Outcomes From TECOS.
Cornel JH; Bakris GL; Stevens SR; Alvarsson M; Bax WA; Chuang LM; Engel SS; Lopes RD; McGuire DK; Riefflin A; Rodbard HW; Sinay I; Tankova T; Wainstein J; Peterson ED; Holman RR;
Diabetes Care; 2016 Dec; 39(12):2304-2310. PubMed ID: 27742728
[TBL] [Abstract][Full Text] [Related]
14. Rationale, design, and organization of a randomized, controlled Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) in patients with type 2 diabetes and established cardiovascular disease.
Green JB; Bethel MA; Paul SK; Ring A; Kaufman KD; Shapiro DR; Califf RM; Holman RR
Am Heart J; 2013 Dec; 166(6):983-989.e7. PubMed ID: 24268212
[TBL] [Abstract][Full Text] [Related]
15. Re-adjudication of the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) with study-level meta-analysis of hospitalization for heart failure from cardiovascular outcomes trials with dipeptidyl peptidase-4 (DPP-4) inhibitors.
Scirica BM; Im K; Murphy SA; Kuder JF; Rodriguez DA; Lopes RD; Green JB; Ruff CT; Sabatine MS
Clin Cardiol; 2022 Jul; 45(7):794-801. PubMed ID: 35715946
[TBL] [Abstract][Full Text] [Related]
16. Assessing the Safety of Sitagliptin in Older Participants in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS).
Bethel MA; Engel SS; Green JB; Huang Z; Josse RG; Kaufman KD; Standl E; Suryawanshi S; Van de Werf F; McGuire DK; Peterson ED; Holman RR;
Diabetes Care; 2017 Apr; 40(4):494-501. PubMed ID: 28057693
[TBL] [Abstract][Full Text] [Related]
17. Low-density lipoprotein cholesterol treatment and outcomes in patients with type 2 diabetes and established cardiovascular disease: Insights from TECOS.
De Ferrari GM; Stevens SR; Ambrosio G; Leonardi S; Armstrong PW; Green JB; Wamil M; Holman RR; Peterson ED;
Am Heart J; 2020 Feb; 220():82-88. PubMed ID: 31790905
[TBL] [Abstract][Full Text] [Related]
18. A randomized, placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus.
Gantz I; Chen M; Suryawanshi S; Ntabadde C; Shah S; O'Neill EA; Engel SS; Kaufman KD; Lai E
Cardiovasc Diabetol; 2017 Sep; 16(1):112. PubMed ID: 28893244
[TBL] [Abstract][Full Text] [Related]
19. Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study).
Mahaffey KW; Neal B; Perkovic V; de Zeeuw D; Fulcher G; Erondu N; Shaw W; Fabbrini E; Sun T; Li Q; Desai M; Matthews DR;
Circulation; 2018 Jan; 137(4):323-334. PubMed ID: 29133604
[TBL] [Abstract][Full Text] [Related]
20. [TECOS: confirmation of the cardiovascular safety of sitaliptin].
Scheen AJ; Paquot N
Rev Med Liege; 2015 Oct; 70(10):511-6. PubMed ID: 26727841
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]